We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Curious about Insulet (PODD) Q1 Performance? Explore Wall Street Estimates for Key Metrics
Read MoreHide Full Article
Wall Street analysts forecast that Insulet (PODD - Free Report) will report quarterly earnings of $0.81 per share in its upcoming release, pointing to a year-over-year increase of 11%. It is anticipated that revenues will amount to $541.33 million, exhibiting an increase of 22.6% compared to the year-ago quarter.
The consensus EPS estimate for the quarter has undergone a downward revision of 1.1% in the past 30 days, bringing it to its present level. This represents how the covering analysts, as a whole, have reassessed their initial estimates during this timeframe.
Prior to a company's earnings release, it is of utmost importance to factor in any revisions made to the earnings projections. These revisions serve as a critical gauge for predicting potential investor behaviors with respect to the stock. Empirical studies consistently reveal a strong link between trends in earnings estimate revisions and the short-term price performance of a stock.
While it's common for investors to rely on consensus earnings and revenue estimates for assessing how the business may have performed during the quarter, exploring analysts' forecasts for key metrics can yield valuable insights.
With that in mind, let's delve into the average projections of some Insulet metrics that are commonly tracked and projected by analysts on Wall Street.
The collective assessment of analysts points to an estimated 'Revenue- Total Omnipod' of $534.28 million. The estimate indicates a change of +23.4% from the prior-year quarter.
Analysts predict that the 'Revenue- Drug Delivery' will reach $7.37 million. The estimate suggests a change of -15.3% year over year.
Analysts expect 'Revenue- International Omnipod' to come in at $144.78 million. The estimate indicates a year-over-year change of +25.6%.
The average prediction of analysts places 'Revenue- U.S. Omnipod' at $389.50 million. The estimate indicates a change of +22.6% from the prior-year quarter.
Over the past month, shares of Insulet have returned +4.8% versus the Zacks S&P 500 composite's +0.4% change. Currently, PODD carries a Zacks Rank #4 (Sell), suggesting that it may underperform the overall market in the near future. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Curious about Insulet (PODD) Q1 Performance? Explore Wall Street Estimates for Key Metrics
Wall Street analysts forecast that Insulet (PODD - Free Report) will report quarterly earnings of $0.81 per share in its upcoming release, pointing to a year-over-year increase of 11%. It is anticipated that revenues will amount to $541.33 million, exhibiting an increase of 22.6% compared to the year-ago quarter.
The consensus EPS estimate for the quarter has undergone a downward revision of 1.1% in the past 30 days, bringing it to its present level. This represents how the covering analysts, as a whole, have reassessed their initial estimates during this timeframe.
Prior to a company's earnings release, it is of utmost importance to factor in any revisions made to the earnings projections. These revisions serve as a critical gauge for predicting potential investor behaviors with respect to the stock. Empirical studies consistently reveal a strong link between trends in earnings estimate revisions and the short-term price performance of a stock.
While it's common for investors to rely on consensus earnings and revenue estimates for assessing how the business may have performed during the quarter, exploring analysts' forecasts for key metrics can yield valuable insights.
With that in mind, let's delve into the average projections of some Insulet metrics that are commonly tracked and projected by analysts on Wall Street.
The collective assessment of analysts points to an estimated 'Revenue- Total Omnipod' of $534.28 million. The estimate indicates a change of +23.4% from the prior-year quarter.
Analysts predict that the 'Revenue- Drug Delivery' will reach $7.37 million. The estimate suggests a change of -15.3% year over year.
Analysts expect 'Revenue- International Omnipod' to come in at $144.78 million. The estimate indicates a year-over-year change of +25.6%.
The average prediction of analysts places 'Revenue- U.S. Omnipod' at $389.50 million. The estimate indicates a change of +22.6% from the prior-year quarter.
View all Key Company Metrics for Insulet here>>>
Over the past month, shares of Insulet have returned +4.8% versus the Zacks S&P 500 composite's +0.4% change. Currently, PODD carries a Zacks Rank #4 (Sell), suggesting that it may underperform the overall market in the near future. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>